More Depressing News For Biovail: Decision On New Wellbutrin Formula Six Months Away
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency has designated Biovail’s complete response to a “not approvable” letter as a class 2 review, giving application an April 23, 2008, action date, as opposed to a class 1 review, which would take only two months.
You may also be interested in...
Biovail Plans Phase III Studies Of Sexual Dysfunction Candidate In 2008
Licensing deal for the product is one of several Biovail intends to enter into to bolster its pipeline.
Biovail NDA For New Wellbutrin Formulation Is “Not Approvable”
FDA had concerns over design of pharmacokinetic studies of once-daily salt formulation of bupropion for depression, the firm says.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.